Skip to main content

Table 1 Clinical characteristics of participants

From: The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

 

Patient group vs control group

Patient group

Controls (N = 26)

Patients (N = 74)

P

aMCI (N = 35)

AD (N = 39)

P

Female (%)

21 (80.8%)

52 (70.3%)

0.30

23 (65.7%)

29 (74.4%)

0.42

Age (year)

68.7 ± 4.2

76.7 ± 8.5

< 0.001

75.6 ± 8.4

77.7 ± 8.5

0.30

Body mass index

23.7 ± 3.3

24.4 ± 3.4

0.38

24.5 ± 3.2

24.3 ± 3.7

0.82

Education (year)

11.4 ± 4.2

8.8 ± 4.9

0.02

9.2 ± 5.1

8.4 ± 4.7

0.51

First MMSE

28.4 ± 0.8

23.9 ± 5.8

< 0.001

26.9 ± 2.3

21.2 ± 6.7

< 0.001

 24–30

26 (100.0%)

50 (67.6%)

0.011

32 (91.4%)

18 (46.2%)

< 0.001

 19–23

0 (0.0%)

11 (14.9%)

 

3 (8.6%)

8 (20.5%)

 

 10–18

0 (0.0%)

12 (16.2%)

 

0 (0%)

12 (30.8%)

 

 0–9

0 (0.0%)

1 (1.4%)

 

0 (0%)

1 (2.6%)

 

Second MMSE

28.4 ± 1.5

22.9 ± 5.8

< 0.001

26.5 ± 2.0

19.7 ± 6.2

< 0.001

Hopkins Verbal Learning Test

23.4 ± 3.7

15.0 ± 4.9

< 0.001

16.7 ± 4.4

13.5 ± 4.9

0.005

Forward digit span

11.7 ± 1.7

9.0 ± 2.6

< 0.001

9.3 ± 2.5

8.6 ± 2.6

0.26

Backward digit span

7.2 ± 2.7

3.8 ± 2.4

< 0.001

4.7 ± 2.3

3.0 ± 2.1

0.001

Trail Making Test Part A

56.7 ± 25.6

115.3 ± 86.5

< 0.001

87.6 ± 67.7

140.2 ± 94.5

0.007

Clinical Dementia Rating

0.04 ± 0.14

1.05 ± 0.72

< 0.001

0.50 ± 0.00

1.54 ± 0.68

< 0.001

Apolipoprotein E ε2:ε3:ε4

7:12:7 (27%:46%:27%)

9:50:15 (12%:68%:20%)

0.109

2:28:5 (6%:80%:14%)

7:22:10 (18%:56%:26%)

0.084

  1. Data are presented as mean ± standard deviation or frequency (percentage)
  2. Abbreviation: aMCI mild cognitive impairment due to Alzheimer’s disease, AD Alzheimer’s disease, MMSE Mini-Mental State Examination